Loading...
9 Philippines Device Drug Combination Reports
Country Covered: Philippines
Study Period: 2019 - 2029
Major Players: Medtronic, Insulet Corporation, Novo Nordisk A/S, Sanofi, F. Hoffmann-La Roche Ltd
Country Covered: Philippines
Study Period: 2019 - 2029
Major Players: Astrazeneca, Astellas, Janssen, Eli Lilly, Sanofi
Country Covered: Philippines
Study Period: 2018 - 2029
Major Players: Medtronics, Roche, NovoNordisk, Sanofi, Omnipod
Country Covered: Philippines
Study Period: 2019 - 2029
Major Players: Biocon, Wockhardt, Novo Nordisk A/S, Eli Lilly and Company, Sanofi Aventis
Country Covered: Philippines
Study Period: 2019 - 2029
Major Players: Novo Nordisk A/S, Medtronic, Dexcom Inc., Abbott Diabetes Care, Roche Diabetes Care
Country Covered: Philippines
Study Period: 2019 - 2029
Major Players: Novo Nordisk, Medtronic, Sanofi, Ypsomed, Eli Lilly and Company
Country Covered: Philippines
Study Period: 2018 - 2029
Major Players: Novo Nordisk, Sanofi, Eli Lilly, Biocon, Julphar
Country Covered: Philippines
Study Period: 2018 - 2029
Major Players: Novo Nordisk, Sanofi, El lilly, Medtronics, Roche
Country Covered: Philippines
Study Period: 2018-2029
Major Players: Abbott, Medtronic, Lilly, Novo Nordisk, Roche